Abstract：OBJECTIVE To investigate the effect of atorvastatin on proliferation and apoptosis of human lung cancer HCC827 cells and explore its mechanism. METHODS The inhibitory effect of atorvastatin on the proliferation of HCC827 cells was detected by trypan blue staining. Cell morphology was observed under optical microscope. Hoechst 33342 and TUNEL assay were used to detect apoptosis. The level of reactive oxygen species (ROS) was detected by DCFH-DA fluorescent probe. Colorimetric method was used to detect the content of malondialdehyde (MDA). The expression levels of P-H2A.X and apoptosis related proteins cleaved-caspase 3, Bax and Bcl-2 were detected by Western blot. RESULTS Atorvastatin inhibits the growth of HCC827 cells and induces apoptosis. The nuclear morphology of HCC827 cells changed and the nucleus showed apoptotic features such as chromatin condensation, crescent shape and so on after atorvastatin treatment. The levels of ROS and MDA were increased with the increase of atorvastatin concentration compared with the control group. Atorvastatin up-regulated the expression of P-H2A.X, cleaved caspase 3 and Bax protein in HCC827 cells, down-regulated the expression of Bcl-2 protein, and up-regulated the ratio of Bax/Bcl-2. CONCLUSION Atorvastatin inhibits proliferation of HCC827 and induces apoptosis, which may be related to oxidative stress and mitochondrial mediated pathway.
赵飘飘, 邵继承, 邓佩佳, 雷蕾, 王楚楚, 陈雪彦, 李军霞. 阿托伐他汀对肺癌HCC827细胞增殖和凋亡的作用[J]. 中国药学杂志, 2020, 55(6): 439-444.
ZHAO Piao-piao, SHAO Ji-cheng, DENG Pei-jia, LEI Lei, WANG Chu-chu, CHEN Xue-yan, LI Jun-xia. Effect of Atorvastatin on Proliferation and Apoptosis of Human Lung Cancer Cell Line HCC827. Chinese Pharmaceutical Journal, 2020, 55(6): 439-444.
JEMAL A, CENTER M M, DESANTIS C, et al. Global patterns of cancer incidence and mortality rates and trends[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(8):1893-1907.
[2]
RUIZ K A,CHIRINO Y I. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection[J]. Biomed Pharmacother, 2017, 90:24-37.
[3]
HERBST R S, HEYMACH J V, LIPPMAN S M. Lung cancer[J]. Ariz Med, 1975, 359(13):189-192.
[4]
PISANTI S, PICARDI P, CIAGLIA E,et al. Novel prospects of statins as therapeutic agents in cancer[J]. Pharmacol Res, 2014, 88(9):84-98.
[5]
LIU Y, TANG W, WANG J, et al. Association between statin use and colorectal cancer risk:a Meta-analysis of 42 studies[J]. Cancer Causes Control, 2014, 25(2):237-249.
[6]
KHURANA V, BEJJANKI H R, CALDITO G,et al. Statins reduce the risk of lung cancer in humans:a large case-control study of US veterans[J]. Chest, 2007, 131(5):1282-1288.
[7]
SHI M, ZHENG H, NIE B,et al. Statin use and risk of liver cancer:an update Meta-analysis[J]. BMJ Open, 2014, 4(9):e005399-e005399.
[8]
LUSTMAN A. Statin use and incident prostate cancer risk:does the statin brand matter? A population-based cohort study[J]. Prostate Cancer Prostatic Dis, 2013, 17(1):6-9.
[9]
NIELSEN S F, NORDESTGAARD B G, BOJESEN S E. Statin use and reduced cancer-related mortality[J]. N Engl J Med, 2012, 367(19):1792-1802.
[10]
OLIVEIRA K A,DAL-CIM T, LOPES F G, et al. Atorvastatin promotes cytotoxicity and reduces migration and proliferation of human A172 glioma cells[J]. Mol Neurobiol, 2018, 55(2):1509-1523.
[11]
KOREN M J, HUNNINGHAKE D B. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics:the alliance study[J]. J Am Coll Cardiol, 2004, 44(9):1772-1779.
[12]
BERNINI F, POLI A, PAOLETTI R. Safety of HMG-CoA reductase inhibitors:focus on atorvastatin[J]. Cardiovasc Drugs Ther, 2001, 15(3):211-218.
[13]
SANG I G, RAHMAN M K, WON J S, et al. A distinctive pattern of beauveria bassiana-biotransformed ginsenoside products triggers mitochondria/FasL-mediated apoptosis in colon cancer cells:PTR[J]. Phytother Res, 2016, 30(1):136-143.
2020, Vol. 55 
